Sugi Predict

Sugi Predict / Compounds / SCHEMBL482949

SCHEMBL482949

SCHEMBL482949

CC(C)(C)c1cc(I)cc(Br)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 1/20 0.47
▸ CISD1 Q9NZ45 1/20 0.47
▸ CA2 P00918 5/20 0.46
▸ CA1 P00915 3/20 0.46
▸ CHEK1 O14757 1/20 0.46
▸ DAPK3 O43293 1/20 0.46
▸ RET P07949 1/20 0.46
▸ PDGFRB P09619 1/20 0.46
▸ PIM1 P11309 1/20 0.46
▸ PDGFRA P16234 1/20 0.46
▸ KDR P35968 1/20 0.46
▸ MAPK8 P45983 1/20 0.46
▸ RPS6KA3 P51812 1/20 0.46
▸ LIMK1 P53667 1/20 0.46
▸ TYRO3 Q06418 1/20 0.46
▸ MAPK14 Q16539 1/20 0.46
▸ LRRK2 Q5S007 1/20 0.46
▸ AURKB Q96GD4 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12574779 0.84 CA2 (0.64) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL896605 0.79 CA1 (0.38) IGF1RCISD1CA2CA1CHEK1
SCHEMBL30218650 0.78 TSHR (0.56) IGF1RCISD1CA2CA1ALDH1A1
SCHEMBL350953 0.78 TTR (0.64) CA2CA1CHEK1DAPK3RET
SCHEMBL1530860 0.78 TSHR (0.56) IGF1RCISD1CA2CA1ALDH1A1
SCHEMBL1628174 0.77 SMN1; SMN2 (0.71) IGF1RCISD1CA2CA1ALDH1A1
SCHEMBL3073021 0.77 TSHR (0.56) IGF1RCISD1CA2CA1CHEK1
SCHEMBL4935468 0.77 CYP3A4 (0.58) CA2CA1CHEK1DAPK3RET
SCHEMBL23092066 0.75 IGF1R (0.47) IGF1RCISD1CA2CA1CHEK1
SCHEMBL5085724 0.75 IGF1R (0.47) IGF1RCISD1CA2CA1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637478-B2 Antiviral compounds and uses thereof ABBVIE INC. (US) 2017-05-02 — — US disclosed
EP-2411352-B1 ANTIVIRAL COMPOUNDS AND USES THEREOF ABBVIE INC (US) 2017-01-18 — — EP disclosed
US-20160368905-A1 ANTIVIRAL COMPOUNDS AND USES THEREOF ABBOTT LABORATORIES 2016-12-22 — — US disclosed
EP-2639226-B1 Anti-infective pyrimidines and uses thereof ABBVIE BAHAMAS LTD (BS) 2016-08-31 — — EP disclosed
US-9353091-B2 Antiviral compounds and uses thereof ABBVIE INC. (US) 2016-05-31 — — US disclosed
US-9139536-B2 Anti-infective agents and uses thereof ABBVIE INC. (US) 2015-09-22 — — US disclosed
US-9095590-B2 Anti-infective agents and uses thereof ABBVIE INC. (US) 2015-08-04 — — US disclosed
US-8986740-B2 Anti-infective agents and uses thereof ABBVIE INC. (US) 2015-03-24 — — US disclosed
US-20150056164-A1 Antiviral Compounds and Uses Thereof ABBVIE INC. (US) 2015-02-26 — — US disclosed
US-20140294766-A1 Anti-Infective Agents and Uses Thereof ABBVIE INC (US) 2014-10-02 — — US disclosed
CN-101842360-A Anti-infective pyrimidines and uses thereof ABBOTT LAB 2010-09-22 — — CN disclosed
EP-2222646-A1 URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Abbott Laboratories (US) 2010-09-01 — — EP disclosed
CN-101801935-A Uracil or thymine derivatives for the treatment of hepatitis C ABBOTT LAB 2010-08-11 — — CN disclosed
EP-2203430-A1 N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS Abbott Laboratories (US) 2010-07-07 — — EP disclosed
EP-2203431-A1 ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF Abbott Laboratories (US) 2010-07-07 — — EP disclosed
US-20090186912-A1 ANTI-INFECTIVE AGENTS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-07-23 — — US disclosed
US-20090176784-A1 ANTI-INFECTIVE AGENTS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-07-09 — — US disclosed
WO-2009039134-A1 ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF ABBOTT LABORATORIES (US) 2009-03-26 — — WO disclosed
WO-2009039127-A1 URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C ABBOTT LABORATORIES (US) 2009-03-26 — — WO disclosed
WO-2009039135-A1 N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS ABBOTT LABORATORIES (US) 2009-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150056164-A1 Antiviral Compounds and Uses Thereof MAVS, ZC3HAV1, EIF2AK2 IGF1R 3944/4885CISD1 2916/4885CA2 3738/4885
US-20090176784-A1 ANTI-INFECTIVE AGENTS AND USES THEREOF MPO, SERPINB1, ELANE IGF1R 4699/4885CISD1 2486/4885CA2 1429/4885
US-20160368905-A1 ANTIVIRAL COMPOUNDS AND USES THEREOF MAVS, ZC3HAV1, EIF2AK2 IGF1R 3944/4885CISD1 2916/4885CA2 3738/4885
US-20140294766-A1 Anti-Infective Agents and Uses Thereof MPO, SERPINB1, ELANE IGF1R 4699/4885CISD1 2486/4885CA2 1429/4885
US-20090186912-A1 ANTI-INFECTIVE AGENTS AND USES THEREOF MPO, SERPINB1, ELANE IGF1R 4699/4885CISD1 2486/4885CA2 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.